Palopegteriparatide
| Clinical data | |
|---|---|
| Trade names | Yorvipath |
| Other names | ACP-014, TransCon PTH |
| AHFS/Drugs.com | Yorvipath |
| License data | |
| Routes of administration | Subcutaneous |
| Drug class | Hormonal agent |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Palopegteriparatide, sold under the brand name Yorvipath, is a hormone replacement therapy used for the treatment of hypoparathyroidism. It is a transiently pegylated parathyroid hormone. It is a parathyroid hormone analog.
Palopegteriparatide was approved for medical use in the European Union in November 2023, and in the United States in August 2024.